BMY Q4 2025 earnings call recap: growth portfolio momentum, pipeline catalysts, 2026 guidance, and Eliquis LOE risks.

Novartis has core profit growth, buybacks, seven clinical readouts, a 5% dividend hike, generic competition, and a 54% FCF ...

A wide of array of advanced controllers arrived in 2025, marked by high integration and enhanced intelligence in solutions ...

Sustained “boots-on-the-ground” community engagement, beyond digital recruitment campaigns, was positioned as a primary lever to improve trial equity and representation. Hesitancy to discuss diversity ...

Class of 2026 consisting of both partners and end customers who deploy ABBYY purpose-built AI solutions at scale in complex, ...

Omisirge transplantation shows accelerated immune recovery in SAANew data presented at the 2026 TANDEM Meetings demonstrate that patients with SAA who received Omisirge experienced faster and more ...

ABB is advancing its Mission to Zero™ program at its Sasbach manufacturing site in Germany, demonstrating how on-site renewable energy, electrification and digital energy management can deliver ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

The prices would reflect discounts the White House said it has negotiated with more than a dozen drug companies under the "most favored nation." ...

The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

Biotech stocks rebounded in 2025. Wedbush’s Laura Chico explains why rare disease catalysts and upcoming data could shape the ...